Is Ocugen stock halal to invest in?

Company Name
Company Symbol
Exchange
Ocugen
OCGN
NASDAQ
OCGN
Halal
Ocugen
NASDAQ

Warning: The result may change based on other methodologies. As of the recent update on Tuesday 7th of February 2023 , is considered as Halal based on FTSE methodology. To access full report and unlock the detailed results with associated ratios for 5 halal investment methodologies, you can click below.

Detailed report based on FTSE methodology

Activity filter

Main Activity
Activity test result
Biotechnology & Medical Research
PASS

Ocugen

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Financial filter

Debt test

Total Debt
Interest free debt
Adjusted debt level
Total Asset
Debt Ratio
PASS or FAIL
$6,470,870
0
$6,470,870
$116,240,000
5.57%
PASS

Cash test

Cash
Cash Eq.
Short Term Investment
Total Asset
Cash & Eq. ratio
PASS or FAIL
$0
$101,600,000
$0
$116,240,000
87.41%
FAIL

Acid test

Cash
Cash Eq.
Net Accounts Receivables
Total Asset
Quick ratio
PASS or FAIL
$0
$101,600,000
$0
$116,240,000
87.41%
FAIL

Non permissible income filter

Net Interest Income (Expense) as non-Operating

Total Non permissible and doubtful income
Total revenue
Non permissible and doubtful income ratio
PASS or FAIL
-$40,000
$0
0%
PASS